Medtronic Announces Intent To Spin Diabetes Business
1. Medtronic plans to spin off its Diabetes segment into a standalone company. 2. Post-spin, Medtronic will focus on core high-margin segments like cardiovascular and neuroscience. 3. The spin-off could enhance Medtronic’s gross margins and earnings per share. 4. Diabetes unit underperformed with only 1.4% CAGR against Medtronic's overall 2.9%. 5. Que Dallara will lead the new Diabetes Company after the spin-off.